312 related articles for article (PubMed ID: 33409252)
1. Targeting Epigenetic 'Readers' with Natural Compounds for Cancer Interception.
Damiani E; Duran MN; Mohan N; Rajendran P; Dashwood RH
J Cancer Prev; 2020 Dec; 25(4):189-203. PubMed ID: 33409252
[TBL] [Abstract][Full Text] [Related]
2. Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells.
Kapoor S; Gustafson T; Zhang M; Chen YS; Li J; Nguyen N; Perez JET; Dashwood WM; Rajendran P; Dashwood RH
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809839
[TBL] [Abstract][Full Text] [Related]
3. Advances in Epigenetic Cancer Therapeutics.
Hillyar C; Rallis KS; Varghese J
Cureus; 2020 Nov; 12(11):e11725. PubMed ID: 33391954
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Sartor GC; Powell SK; Brothers SP; Wahlestedt C
J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
[TBL] [Abstract][Full Text] [Related]
5. Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.
Rajendran P; Johnson G; Li L; Chen YS; Dashwood M; Nguyen N; Ulusan A; Ertem F; Zhang M; Li J; Sun D; Huang Y; Wang S; Leung HC; Lieberman D; Beaver L; Ho E; Bedford M; Chang K; Vilar E; Dashwood R
Cancer Res; 2019 Mar; 79(5):918-927. PubMed ID: 30643017
[TBL] [Abstract][Full Text] [Related]
6. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
Wahi A; Manchanda N; Jain P; Jadhav HR
Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
[TBL] [Abstract][Full Text] [Related]
7. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Regulation of p21
Ocker M; Bitar SA; Monteiro AC; Gali-Muhtasib H; Schneider-Stock R
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31514410
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Priming and Development of New Combination Therapy Approaches.
Meneceur S; Grunewald CM; Niegisch G; Hoffmann MJ
Methods Mol Biol; 2023; 2684():259-281. PubMed ID: 37410240
[TBL] [Abstract][Full Text] [Related]
10. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Regulation of NRF2/KEAP1 by Phytochemicals.
Bhattacharjee S; Dashwood RH
Antioxidants (Basel); 2020 Sep; 9(9):. PubMed ID: 32938017
[TBL] [Abstract][Full Text] [Related]
12. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
13. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs.
Muddassir M; Soni K; Sangani CB; Alarifi A; Afzal M; Abduh NAY; Duan Y; Bhadja P
RSC Adv; 2020 Dec; 11(2):612-636. PubMed ID: 35746919
[TBL] [Abstract][Full Text] [Related]
15. Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy.
Stratton MS; McKinsey TA
Biochem Cell Biol; 2015 Apr; 93(2):149-57. PubMed ID: 25707943
[TBL] [Abstract][Full Text] [Related]
16. BET domain co-regulators in obesity, inflammation and cancer.
Belkina AC; Denis GV
Nat Rev Cancer; 2012 Jun; 12(7):465-77. PubMed ID: 22722403
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
[TBL] [Abstract][Full Text] [Related]
18. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of BDNF Expression and Memory by HDAC Inhibition Requires BET Bromodomain Reader Proteins.
Sartor GC; Malvezzi AM; Kumar A; Andrade NS; Wiedner HJ; Vilca SJ; Janczura KJ; Bagheri A; Al-Ali H; Powell SK; Brown PT; Volmar CH; Foster TC; Zeier Z; Wahlestedt C
J Neurosci; 2019 Jan; 39(4):612-626. PubMed ID: 30504275
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
